ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics is attractive because AX-0810 has already shown human proof of concept with a favorable safety profile, no severe adverse events, no discontinuations, and no clinically significant liver enzyme, bilirubin, hormone, or vitamin D changes. The platform also produced dose-dependent pharmacology, including up to an 8-fold rise in serum total bile acids, increased circulating TUDCA, and higher plasma conjugated bile acids, supporting clear NTCP target engagement while preserving other transporter functions. In addition, AX-0811 appears mechanistically stronger, with preclinical data suggesting 40% to 65% human liver editing, a projected 3-plus-month half-life, and the potential for longer dosing intervals, while the $50 million offering and $9.2 million private placement extend runway into 2H28 to fund the next readouts.

ProQR Therapeutics is facing a difficult path as its RNA pipeline remains highly exposed to clinical, regulatory, and execution risk, especially in the newly prioritized biliary atresia program where patient enrichment, biomarker selection, and narrow proof-of-concept design could limit readout quality. The company also burns cash and may need additional debt or equity financing, which could be dilutive and difficult to secure on acceptable terms, while regulators may disagree with its data or approve narrower indications than sought. Meanwhile, intense competition from better-resourced biotechnology and pharmaceutical rivals in RNA medicines, gene therapy, and small molecules raises the risk that ProQR’s therapies become non-competitive or obsolete before commercialization.